These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 24251651

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [Long-term low-dose secondary prophylaxis for severe and moderate hemophilia children with arthropathy in China: a single-center observation study].
    Wu RH, Wu XY, Zhang NN, Zhao L, Zhang JS, Zhen YZ, Peng Y.
    Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):632-4. PubMed ID: 23906463
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
    Ho S, Gue D, McIntosh K, Bucevska M, Yang M, Jackson S.
    Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C, Watts RG.
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of enhanced half-life factor VIII and IX in the treatment of haemophilia.
    Mahdi AJ, Obaji SG, Collins PW.
    Br J Haematol; 2015 Jun; 169(6):768-76. PubMed ID: 25754016
    [Abstract] [Full Text] [Related]

  • 9. Changing paradigm of prophylaxis with longer acting factor concentrates.
    Carcao M.
    Haemophilia; 2014 May; 20 Suppl 4():99-105. PubMed ID: 24762284
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Central venous access catheters in children with haemophilia.
    Blanchette VS, al-Musa A, Stain AM, Filler RM, Ingram J.
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S39-44. PubMed ID: 8735796
    [Abstract] [Full Text] [Related]

  • 13. What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
    Petrini P.
    Haemophilia; 2001 Jan; 7(1):99-102. PubMed ID: 11136389
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries.
    Ljung R, Aronis-Vournas S, Kurnik-Auberger K, van den Berg M, Chambost H, Claeyssens S, van Geet C, Glomstein A, Hann I, Hill F, Kobelt R, Kreuz W, Mancuso G, Muntean W, Petrini P, Rosado L, Scheibel E, Siimes M, Smith O, Tusell J.
    Haemophilia; 2000 Nov; 6(6):619-24. PubMed ID: 11122385
    [Abstract] [Full Text] [Related]

  • 16. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors.
    Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY.
    Haemophilia; 2014 Jan; 20(1):65-72. PubMed ID: 23910578
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B.
    Wang C, Young G.
    Haemophilia; 2018 May; 24(3):414-419. PubMed ID: 29405496
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.